Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. News
Protalix BioTherapeutics, Inc. Quantitative Score
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Protalix BioTherapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Protalix BioTherapeutics, Inc. Financials
Table Compare
Compare PLX metrics with: | |||
|---|---|---|---|
Earnings & Growth | PLX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PLX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PLX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PLX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Protalix BioTherapeutics, Inc. Income
Protalix BioTherapeutics, Inc. Balance Sheet
Protalix BioTherapeutics, Inc. Cash Flow
Protalix BioTherapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Protalix BioTherapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Dror Bashan | President, Chief Executive Officer & Director |
| Mr. Yaron Naos B.Sc., MBA | Senior Vice President of Operations |
| Ms. Yael Fellous | Vice President of Human Resources |
| Mr. Gilad Mamlok | Senior Vice President & Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Dror Bashan | President, Chief Executive Officer & Director | Male | 1967 | 490.67K |
| Mr. Yaron Naos B.Sc., MBA | Senior Vice President of Operations | Male | 1964 | 396.47K |
| Ms. Yael Fellous | Vice President of Human Resources | Female | -- | |
| Mr. Gilad Mamlok | Senior Vice President & Chief Financial Officer | Male | 1968 | -- |
Protalix BioTherapeutics, Inc. Insider Trades
| Date | 3 Sep |
| Name | Melincoff Gwen A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7500 |
| Date | 3 Sep |
| Name | Melincoff Gwen A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 3 Sep |
| Name | Forster Eliot |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7500 |
| Date | 3 Sep |
| Name | Forster Eliot |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 3 Sep |
| Name | Boudes Pol F |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7500 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Sep | Melincoff Gwen A | Director | Acquired | A-Award | 7500 |
| 3 Sep | Melincoff Gwen A | Director | Acquired | A-Award | 15000 |
| 3 Sep | Forster Eliot | Director | Acquired | A-Award | 7500 |
| 3 Sep | Forster Eliot | Director | Acquired | A-Award | 15000 |
| 3 Sep | Boudes Pol F | Director | Acquired | A-Award | 7500 |